Long- and Short-Term Glucosphingosine (lyso-Gb1) Dynamics in Gaucher Patients Undergoing Enzyme Replacement Therapy
Biomolecules · 2024
DOI: 10.3390/biom14070842 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Pawel Dubiela und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, 15-089 Bialystok, Poland. Hauptthemen laut MEDLINE: Gaucher Disease, Enzyme Replacement Therapy, Glucosylceramidase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Children's Memorial Health Institute and Medical Research Agency, Medical Research Agency (Poland).
Abstract (Originalsprache)
Background
Gaucher disease (GD) is a lysosomal storage disorder caused by mutations in the GBA1 gene, leading to β-glucocerebrosidase deficiency and glucosylceramide accumulation.
Methods
We analyzed short- and long-term dynamics of lyso-glucosylceramide (lyso-Gb1) in a large cohort of GD patients undergoing enzyme replacement therapy (ERT).
Results
Eight-years analysis of lyso-Gb1 revealed statistically insignificant variability in the biomarker across the years and relatively high individual variability in patients’ results. GD type 1 (GD1) patients exhibited higher variability compared to GD type 3 (GD3) patients (coefficients of variation: 34% and 23%, respectively; p-value = 0.0003). We also investigated the short-term response of the biomarker to enzyme replacement therapy (ERT), measuring lyso-Gb1 right before and 30 min after treatment administration. We tested 20 GD patients (16 GD1, 4 GD3) and observed a rapid and significant reduction in lyso-Gb1 levels (average decrease of 17%; p-value < 0.0001). This immediate response reaffirms the efficacy of ERT in reducing substrate accumulation in GD patients but, on the other hand, suggests the biomarker’s instability between the infusions.
Conclusions
These findings underscore lyso-Gb1’s potential as a reliable biomarker for monitoring efficacy of treatment. However, individual variability and dry blood spot (DBS) testing limitations urge a further refinement in clinical application. Our study contributes valuable insights into GD patient management, emphasizing the evolving role of biomarkers in personalized medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, 15-089 Bialystok, Poland.
- Department of Pathophysiology and Allergy Research, Medical University of Vienna, 1090 Vienna, Austria.
- Faculty of Mathematics, Informatics and Mechanics, University of Warsaw, 00-927 Warsaw, Poland.
- Department of Internal Medicine and Gastroenterology, Municipal Hospital, 43-100 Tychy, Poland.
- Institute of Clinical Sciences, Maria Skłodowska-Curie Medical Academy, 00-136 Warsaw, Poland.
- Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania.
ORCID-Profile: Pawel Dubiela, Piotr Hasinski, Patryk Lipinski, Dorota Giersz, Anna Tylki-Szymanska
Förderung
- The Children's Memorial Health Institute and Medical Research Agency
- Medical Research Agency (Poland)
Zitieren
APA
Dubiela, P., Szymanska-Rozek, P., Hasinski, P., Lipinski, P., Kleinotiene, G., Giersz, D., & Tylki-Szymanska, A. (2024). Long- and Short-Term Glucosphingosine (lyso-Gb1) Dynamics in Gaucher Patients Undergoing Enzyme Replacement Therapy. Biomolecules. https://doi.org/10.3390/biom14070842
Vancouver
Dubiela P, Szymanska-Rozek P, Hasinski P, Lipinski P, Kleinotiene G, Giersz D, et al. Long- and Short-Term Glucosphingosine (lyso-Gb1) Dynamics in Gaucher Patients Undergoing Enzyme Replacement Therapy. Biomolecules. 2024. doi:10.3390/biom14070842
BibTeX
@article{Dubiela2024,
author = {Dubiela, Pawel and Szymanska-Rozek, Paulina and Hasinski, Piotr and Lipinski, Patryk and Kleinotiene, Grazina and Giersz, Dorota and Tylki-Szymanska, Anna},
title = {Long- and Short-Term Glucosphingosine (lyso-Gb1) Dynamics in Gaucher Patients Undergoing Enzyme Replacement Therapy},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14070842}
}
EUVIMED